 that I love that you don't see everywhere (read: WWE). AEW isn't a perfect product but it's what I want out of a weekly pro wrestling show.
Sadly, PAC was made to look like a schmuck on the last show -- not just that he couldn't beat a one-eyed Moxley, but just how. freaking. LONG he stood on the top rope before trying not just the first splash, but ALSO the Black Arrow afterwards. I think I noticed this especially because I was so annoyed at the audio issues (the fluctuating volume levels and the constant muting of the crowd chants) that I muted my volume and did my own commentary for my wife (who is blind). How anyone can buy him as a credible main eventer after that, I do not know, and it pissed me off.
That wasn't my only issue with this show, either. It may have been the worst one they've done to date that didn't involve Dark Order or Nightmare Collective. The only real positive was the opening tag match -- I am really digging the whole angle with Page/Omega/Young Bucks, and though I was dubious when I read the spoilers regarding the tag title change, it really was done well. Everything else was, at best, just kinda there.

Up until now, I never really had any strong feelings about Sonny Kiss, mainly because I hadn't seen enough of him to care one way or the other.  As he was making his comeback against Stu Grayson, he hit four or five moves in a row, culminating in his slingshot split-legdrop. Then, after all that, with absolutely no offense in-between by Grayson, suddenly Sonny is in such dire straits that he has to crawl across the ring to tag in Brandon Cutler (and get cut off). Not only did he look perfectly fine for the thirty seconds before that, he had at least three opportunities to just walk over and tag Cutler, but instead he had to get his moves in or whatever. I literally rage-quit watching the show, it was that bad.
Go back to training, Sonny. You are not ready.
Also note: I would love to make a comment about Dynamite -- to which end it would be nice to, you know, ACTUALLY BE ABLE TO WATCH DYNAMITE. I cannot find this week's show on Sling's On Demand feature, nor can I find last week's show that I watched last Friday (and had to find under Season 1, even though the 1/8 episode is listed under season 2). This has been very hit-or-miss since day one, to the point that I have had at times to resort to...um...being that thing the Inner Circle jibes Jon Moxley about being in order to watch the show at any time other than live. It doesn't help that the naming of the shows is very inconsistent -- all the early episodes are just labeled "AEW Dynamite", without even a date to tell which is which.
Amateur hour, guys. Maybe Sonny Kiss is fine where he is after all.

So, on the most recent Dark, you have an intergender tag match, in which Riho takes part and spends considerable time being beaten by Kip Sabian, with Omega trumpeting it to the high heavens as some kind of progressive thing. Then, THE VERY NEXT F'ING NIGHT on Dynamite you have Riho being treated as something akin to a damsel-in-distress when threatened by PAC?
Bull. F'ing. Shit. You don't get to eat your cake and have it, too, people. I'm running out of slack to give you.
Well at least the Nightmare Collective thing didn't last. Although I always have, still, and always will find Brandi Rhodes annoying as an actual wrestling personality. Should stick to ring announcing.
PAC is a lot more menacing than Kip Sabian. The former is sadistic and kind of psycho, the latter is just a cocky jerk. Also, it was a tag match.
In WWE terms: imagine Becky Lynch vs Rio Rush. Then imagine Becky Lych vs Braun Strowman.
That all said, Riho is so tiny she makes Marko Stunt look intimidating.While chemoprevention with botanicals displays promise in reducing malignancy risk recruitment and retention of participants for trials continues to be costly and presents unique challenges. evaluating a botanical agent for lung cancer prevention. Over 92% of subjects reported willingness to comply with study requirements; multiple blood draws and outings to the Center spiral CTs and chest x-rays. Subjects were relatively less enthusiastic (73-79%) about bronchoscopy taking multiple study brokers and assignment to placebo arm. Conclusions Our study strongly suggests feasibility highlights potential challenges and the significant interest and willingness of this exceptionally high risk population to participate in chemoprevention trials. Keywords: Former smokers Chemoprevention Lung Cancer Introduction Lung cancer is the leading cause of cancer-related deaths in both men and women NOS2A in the United EKB-569 States EKB-569 as well the leading cause of malignancy death worldwide [1]. The WHO/International Association now recognizes distinct histological lesions which can be reproducibly graded as precursors of lung cancer. Lung EKB-569 carcinogenesis begins from normal bronchial epithelium and progresses to hyperplasia metaplasia dysplasia carcinoma insitu to invasive malignancy [2-6]. Nearly 90% of lung cancer patients have a history of smoking and over 50% of new lung cancers develop among individuals who’ve previously stop smoking [1]. Furthermore to ways of sustain smoking cigarettes cessation previous smokers could be a motivated focus on inhabitants for chemoprevention [2 7 Distinct top features of lung cancers such as for example significant mortality and morbidity; longer latency; option of histological lesions as an intermediate stage of lung cancers progression; as well as the high prevalence of US former smokers provide a rationale and opportunity for evaluating brokers for chemoprevention in this target population. Chemoprevention thus represents an integral part of the future of lung malignancy control. Several brokers have been evaluated for the chemoprevention of lung malignancy. Cox-2 inhibitors non-steroidal anti-inflammatory drugs (NSAIDs) and enzastaurin (LY317615) have been evaluated for EKB-569 the chemoprevention of lung malignancy in former or current smokers. However poor effectiveness or cardiovascular and other toxicities have limited their clinical adoption [8 9 Other chemopreventive brokers evaluated include beta-carotene alpha-tocopherol retinol retinyl palmitate N-acetylcysteine or isotretinoin [10-13]. Lung cancers were not prevented by these brokers and increased lung malignancy risk and toxicities were reported in specific subgroubs establishing the need to identify alternative chemoprevention brokers with a more favorable safety profile. Experience from these previous efforts with lung malignancy chemoprevention including the CARET [14] and ATBC [15] trials have clearly exhibited the need for more thorough preclinical and early phase work to better understand agent security dose and mechanism of action. Botanicals have been shown to influence multiple biochemical and molecular cascades that inhibit mutagenesis proliferation induce apoptosis suppress the formation and growth of human cancers thus modulating several hallmarks EKB-569 of carcinogenesis with a significantly superior security profile than most brokers evaluated to date in addition to a long history of use in the human population 38-41. However unlike other trials with experimental drugs or vitamins and minerals chemoprevention trials using botanicals present unique difficulties to recruitment 12. We as well as others have observed several barriers to recruitment in chemoprevention trials using EKB-569 botanicals including research environment protocol and subject related factors [16]. Although institutional databases mass media and community outreach efforts to recruit participation in clinical trials have demonstrated success in epidemiological studies and treatment trials we have not experienced the same success in recruitment to early phase trials with FDA approved botanicals [14 15 Similarly marketing of the protocol to community physicians and staff using study specific tested (literacy level and cultural sensitivity) [17] recruitment resources and personal visits by principal investigators to discuss study specific.
Crafting State-Nations: India and Other Multinational Democracies
JHU Press, Mar 31, 2011 - Political Science - 308 pages
Political wisdom holds that the political boundaries of a state necessarily coincide with a nation's perceived cultural boundaries. Today, the sociocultural diversity of many polities renders this understanding obsolete. This volume provides the framework for the state-nation, a new paradigm that addresses the need within democratic nations to accommodate distinct ethnic and cultural groups within a country while maintaining national political coherence.
First introduced briefly in 1996 by Alfred Stepan and Juan J. Linz, the state-nation is a country with significant multicultural—even multinational—components that engenders strong identification and loyalty from its citizens. Here, Indian political scholar Yogendra Yadav joins Stepan and Linz to outline and develop the concept further. The core of the book documents how state-nation policies have helped craft multiple but complementary identities in India in contrast to nation-state policies in Sri Lanka, which contributed to polarized and warring identities. The authors support their argument with the results of some of the largest and most original surveys ever designed and employed for comparative political research. They include a chapter discussing why the U.S. constitutional model, often seen as the preferred template for all the world’s federations, would have been particularly inappropriate for crafting democracy in politically robust multinational countries such as India or Spain. To expand the repertoire of how even unitary states can respond to territorially concentrated minorities with some secessionist desires, the authors develop a revised theory of federacy and show how such a formula